Drawing for MINDLIGHT

USPTO serial 98585696

MINDLIGHT

Reviewed by CopyMark Law Group

Reg. 7978197Status 700Registered
Filing date
Status date
Registration date
Oct 7, 2025
Examiner
MMEJE, OBIEZE GINIKANWA
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with MINDLIGHT?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

David S. Kerr

David S. Kerr Berg Hill Greenleaf Ruscitti LLP1712 Pearl St.Boulder, CO 80302United States

Goods and services

ClassDescriptionStatusFirst use
044Medical laboratory analysis services relating to the treatment of persons, namely, detecting circular RNA biomarkers for medical purposes; Medical laboratory analysis services relating to the treatment of persons, namely, detecting circular RNA biomarkers for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of persons, namely, namely detecting circular RNA biomarkers for the diagnostic assessment of a major depressive disorder (MDD); Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for the diagnosis of a major depression disorder; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers for medical purposes; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for major depressive disorders (MDD); Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for predicting patient response to selective serotonin reuptake inhibitor (SSRI) and disease prognosis based on SSRI treatment; and Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for predicting patient response to SSRI for treatment of major depressive disorder (MDD) and predicting disease prognosis following treatmentACTIVENov 1, 2024

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 7, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 7, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 15, 2025SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Sep 15, 2025CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jul 2, 2025SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jul 1, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Mar 28, 2025IUAFUSE AMENDMENT FILED—
Mar 28, 2025EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Mar 25, 2025NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jan 28, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 28, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 22, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 7, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 18, 2024DOCKASSIGNED TO EXAMINER—
Dec 17, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 5, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance